Join the Ulcerative Colitis group to help and get support from people like you.
Ulcerative Colitis News (Page 2)
Related terms: Colitis, Ulcerative, UC, Colitis Ulcerosa
Crohn's, Colitis Care Take Big Financial Toll on Patients
THURSDAY, Oct. 10, 2024 – Inflammatory bowel conditions such as Crohn’s disease and colitis cause intense financial pressure as well as physical distress, a new study shows. More than 40% of people w...
Anti-TL1A Monoclonal Antibody, Tulisokibart, Aids Ulcerative Colitis
FRIDAY, Oct. 4, 2024 – Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to severely active...
FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar to Stelara
September 30, 2024 – Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic...
Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis
HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya® (guselkumab) for the treatment of adults with m...
Treatment Could Be New Option for People Battling Ulcerative Colitis
FRIDAY, Sept. 27, 2024 – An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The...
FDA Approves Tremfya for Ulcerative Colitis
MONDAY, Sept. 16, 2024 – The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. Tremfya is the...
RSV Infection With Inflammatory Bowel Disease Ups Risk for Hospitalization
WEDNESDAY, Aug. 28, 2024 – Adult patients with inflammatory bowel disease (IBD) and respiratory syncytial virus (RSV) infection have an increased risk for hospitalization, according to a study...
Televisit Outpatient Care Feasible for Inflammatory Bowel Disease
FRIDAY, Aug. 23, 2024 – Televisit-delivered outpatient care for inflammatory bowel disease (IBD) is not associated with a higher risk for IBD-related hospitalization, according to a study published...
4 Tips to Keeping Your Gut Healthy and Free of IBD
TUESDAY, Aug. 6, 2024 – Almost 2.4 million Americans are thought to suffer from the pain and disability of inflammatory bowel disorder (IBD), a type of autoimmune illness that includes ulcerative...
'Microrobot' Pills Eased IBD in Mice, Paving Way for Human Testing
FRIDAY, June 28, 2024 – A new "microrobot" pill may help tame inflammatory bowel disease (IBD), a new study in mice suggests. The pill significantly reduced IBD symptoms in mice and promoted the...
FDA Approves Skyrizi (risankizumab-rzaa) for Ulcerative Colitis
NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Skyrizi® (risankizumab-rzaa) for adults with moderately ...
No Link Seen Between Exposure to Immunosuppressive Therapy, Cancer in IBD Patients
TUESDAY, June 11, 2024 – There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory bowel disease (IBD)...
Risk for Most Cardiovascular Diseases No Higher With Inflammatory Bowel Disease
FRIDAY, May 3, 2024 – Among postmenopausal women with inflammatory bowel disease (IBD), there is no higher risk for cardiovascular disease (CVD) compared with women without IBD, although the risk...
FDA Approves Simlandi (adalimumab-ryvk), an Interchangeable Biosimilar to Humira
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) – Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
FDA Approves Wezlana (ustekinumab-auub), an Interchangeable Biosimilar to Stelara
October 31, 2023 – Today, the U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory...
Further information
Related condition support groups
Ulcerative Colitis - Active, Colitis
Related drug support groups
Humira, clonidine, hydrocortisone, Stelara, Entyvio, Remicade, Xeljanz, Skyrizi, dexamethasone, adalimumab, budesonide, ustekinumab